Skip to content

UroGen Pharma URGN Inventories

Inventories at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.76B+3.4%
Pfizer logo
PfizerPFE
$2.46B-11.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.58B+15.2%
Merck & Co. logo
Merck & Co.MRK
$6.2B+36.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$18.86M+123%
CG Oncology logo
CG OncologyCGON
$1.49M

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's inventories?
UroGen Pharma (URGN) reported inventories of $20.92M in Q1 2026.
How has UroGen Pharma's inventories changed year-over-year?
UroGen Pharma's inventories increased by 175.6% year-over-year, from $7.59M to $20.92M.
What is the long-term trend for UroGen Pharma's inventories?
Over 5 years (2020 to 2025), UroGen Pharma's inventories has grown at a 53.0% compound annual growth rate (CAGR), from $1.96M to $16.46M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.